Jee-Ae Kim1, Min Kyoung Lim2, Kunil Kim3, JuHee Park1, Chin Kook Rhee4. 1. Health Insurance Review and Assessment Service, Pharmaceutical Policy Research Team, Research Institution, Wonju, South Korea. 2. Department of Nursing, Shinhan University, Seoul, South Korea. 3. Department of Radiology, Pusan National University, Yangsan Hospital, Yangsan, South Korea. 4. Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222 Banpodaero, Seochogu, Seoul, 06591, South Korea. chinkook77@gmail.com.
Abstract
BACKGROUND: Adherence to inhaled medication regimens affects chronic obstructive pulmonary disease (COPD) prognosis and quality of life, and reduces the use of healthcare services, resulting in cost savings. OBJECTIVES: To examine the effects of adherence to inhaled medication regimens on healthcare utilization and costs in high-grade COPD patients. METHODS: We performed an observational retrospective cohort study using a longitudinal data set from the Korean Health Insurance Review and Assessment Service (2008-2013) containing healthcare services' information for 50 million beneficiaries. The study population was high-grade COPD patients. "Adherent" was defined as a patient attaining a medication possession ratio (MPR) ≥ 80%. We estimated the effects of adherence on the use of intensive care units (ICUs) and emergency rooms (ERs) using a multivariate logistic regression, and estimated the effects on costs (all-cause and COPD-related) using a generalized linear model, with adjustment for patient sociodemographic characteristics, health status, and comorbidities. RESULTS: Of 9086 high-grade COPD patients, adherence declined from 34.7 to 22.3% over 4 years. Adherence was inversely associated with use of ICUs and costs, and this association got stronger as the adherence period lengthened. Over the 4-year period, the adherent group had a lower likelihood of using ICUs [odds ratio (OR) = 0.74, 95% confidence interval (CI) 0.60-0.91] than the non-adherent group. Similarly, the adherent group had a 10.4% lower all-cause cost (p < 0.001) and an 11.7% lower COPD-related cost (p < 0.0001) versus the non-adherent group. CONCLUSIONS: Adherence reduces healthcare utilization and costs, so adherence is not only clinically effective but also economically efficient. However, less than one-quarter of this population remained adherent over the 4-year period, suggesting that strategies are needed to improve adherence.
BACKGROUND: Adherence to inhaled medication regimens affects chronic obstructive pulmonary disease (COPD) prognosis and quality of life, and reduces the use of healthcare services, resulting in cost savings. OBJECTIVES: To examine the effects of adherence to inhaled medication regimens on healthcare utilization and costs in high-grade COPD patients. METHODS: We performed an observational retrospective cohort study using a longitudinal data set from the Korean Health Insurance Review and Assessment Service (2008-2013) containing healthcare services' information for 50 million beneficiaries. The study population was high-grade COPD patients. "Adherent" was defined as a patient attaining a medication possession ratio (MPR) ≥ 80%. We estimated the effects of adherence on the use of intensive care units (ICUs) and emergency rooms (ERs) using a multivariate logistic regression, and estimated the effects on costs (all-cause and COPD-related) using a generalized linear model, with adjustment for patient sociodemographic characteristics, health status, and comorbidities. RESULTS: Of 9086 high-grade COPD patients, adherence declined from 34.7 to 22.3% over 4 years. Adherence was inversely associated with use of ICUs and costs, and this association got stronger as the adherence period lengthened. Over the 4-year period, the adherent group had a lower likelihood of using ICUs [odds ratio (OR) = 0.74, 95% confidence interval (CI) 0.60-0.91] than the non-adherent group. Similarly, the adherent group had a 10.4% lower all-cause cost (p < 0.001) and an 11.7% lower COPD-related cost (p < 0.0001) versus the non-adherent group. CONCLUSIONS: Adherence reduces healthcare utilization and costs, so adherence is not only clinically effective but also economically efficient. However, less than one-quarter of this population remained adherent over the 4-year period, suggesting that strategies are needed to improve adherence.
Authors: Edmond L Toy; Nicolas U Beaulieu; Joshua M McHale; Timothy R Welland; Craig A Plauschinat; Andrine Swensen; Mei Sheng Duh Journal: Respir Med Date: 2010-09-29 Impact factor: 3.415
Authors: Linda Simoni-Wastila; Yu-Jung Wei; Jingjing Qian; Ilene H Zuckerman; Bruce Stuart; Thomas Shaffer; Anand A Dalal; Lynda Bryant-Comstock Journal: Am J Geriatr Pharmacother Date: 2012-04-21
Authors: J Vestbo; J A Anderson; P M A Calverley; B Celli; G T Ferguson; C Jenkins; K Knobil; L R Willits; J C Yates; P W Jones Journal: Thorax Date: 2009-08-23 Impact factor: 9.139
Authors: Carl Victor Asche; Shelah Leader; Craig Plauschinat; Swetha Raparla; Ming Yan; Xiangyang Ye; Dave Young Journal: Int J Chron Obstruct Pulmon Dis Date: 2012-03-15
Authors: Ruben D Restrepo; Melissa T Alvarez; Leonard D Wittnebel; Helen Sorenson; Richard Wettstein; David L Vines; Jennifer Sikkema-Ortiz; Donna D Gardner; Robert L Wilkins Journal: Int J Chron Obstruct Pulmon Dis Date: 2008
Authors: JinHee Kim; Chin Kook Rhee; Kwang Ha Yoo; Young Sam Kim; Sei Won Lee; Yong Bum Park; Jin Hwa Lee; YeonMok Oh; Sang Do Lee; Yuri Kim; KyungJoo Kim; HyoungKyu Yoon Journal: Int J Chron Obstruct Pulmon Dis Date: 2013-11-19
Authors: Evalyne M Jansen; Susanne J van de Hei; Boudewijn J H Dierick; Huib A M Kerstjens; Janwillem W H Kocks; Job F M van Boven Journal: J Thorac Dis Date: 2021-06 Impact factor: 2.895